帕博利珠单抗治疗后胸腺癌患者长期随访的持久应答。
Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
机构信息
Weill Cornell Medicine, Cornell University, New York, New York; Georgetown, Washington, District of Columbia.
Weill Cornell Medicine, Cornell University, New York, New York; Georgetown, Washington, District of Columbia.
出版信息
J Thorac Oncol. 2021 Mar;16(3):483-485. doi: 10.1016/j.jtho.2020.11.003. Epub 2020 Nov 25.
Here, we present an update of a phase 2 study of pembrolizumab in patients with advanced thymic carcinoma who failed previous therapies. Duration of response was approximately 3 years, and median survival was in excess of 2 years with a 5-year survival rate of 18%. The higher than expected incidence of severe autoimmune disorders (15%) did not substantially increase with a longer follow-up. Pembrolizumab induces durable responses in patients with thymic carcinoma. Careful selection of patients and monitoring of toxicities are warranted.
在这里，我们报告了一项帕博利珠单抗治疗既往治疗失败的晚期胸腺癌患者的 2 期研究更新结果。缓解持续时间约为 3 年，中位总生存期超过 2 年，5 年生存率为 18%。尽管随访时间延长，但严重自身免疫性疾病（15%）的发生率高于预期，并未显著增加。帕博利珠单抗可诱导胸腺癌患者产生持久缓解。需要仔细选择患者并监测毒性。
Zotero 插件